Cargando…

Cost of tumor necrosis factor blockers per patient with rheumatoid arthritis in a multistate Medicaid population

BACKGROUND: The purpose of this study was to estimate the annual cost per treated patient for the tumor necrosis factor (TNF) blockers, etanercept, adalimumab, and infliximab in rheumatoid arthritis (RA) patients covered by Medicaid. METHODS: The MarketScan Medicaid Multistate Database was used to i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bonafede, Machaon, Joseph, George J, Shah, Neel, Princic, Nicole, Harrison, David J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4168856/ https://www.ncbi.nlm.nih.gov/pubmed/25246804 http://dx.doi.org/10.2147/CEOR.S61445

Ejemplares similares

Etanercept‐Methotrexate Combination Therapy Initiators Have Greater Adherence and Persistence Than Triple Therapy Initiators With Rheumatoid Arthritis
por: Bonafede, Machaon, et al.
Publicado: (2015)

Reducing the Cost of Medicaid: A Multistate Simulation
por: Linder, Stephen H, et al.
Publicado: (2018)

Real-world analysis of cost, health care resource utilization, and supportive care in Hodgkin lymphoma patients with frontline failure
por: Bonafede, Machaon, et al.
Publicado: (2018)

Effectiveness and Costs Among Rheumatoid Arthritis Patients Treated with Targeted Immunomodulators Using Real-World U.S. Data
por: Gharaibeh, Mahdi, et al.
Publicado: (2020)

The burden of cystic fibrosis in the Medicaid population
por: Hassan, Mariam, et al.
Publicado: (2018)

Treatment effectiveness and treatment patterns among rheumatoid arthritis patients after switching from a tumor necrosis factor inhibitor to another medication
por: Bonafede, Machaon MK, et al.
Publicado: (2016)

Biologic Cost per Effectively Treated Rheumatoid Arthritis Patient in a Large Managed Care Population: A Retrospective Cohort Study
por: Gu, Tao, et al.
Publicado: (2015)

Importance of the Medicaid Medical Directors’ Multistate Collaborative for Improving Care in Medicaid
por: Zerzan, Judy, et al.
Publicado: (2014)

Retrospective database analysis of clinical outcomes and costs for treatment of abnormal uterine bleeding among women enrolled in US Medicaid programs
por: Bonafede, Machaon M, et al.
Publicado: (2014)

Costs of Tumor Necrosis Factor Blockers Per Treated Patient Using Real-World Drug Data in a Managed Care Population
por: Schabert, Vernon F., et al.
Publicado: (2013)

Cost-Effectiveness of Global Endometrial Ablation vs. Hysterectomy for Treatment of Abnormal Uterine Bleeding: US Commercial and Medicaid Payer Perspectives
por: Miller, Jeffrey D., et al.
Publicado: (2015)

Medication Effectiveness with the Use of Tumor Necrosis Factor Inhibitors Among Texas Medicaid Patients Diagnosed with Rheumatoid Arthritis
por: Oladapo, Abiola, et al.
Publicado: (2014)

Cost effectiveness of endometrial ablation with the NovaSure(®) system versus other global ablation modalities and hysterectomy for treatment of abnormal uterine bleeding: US commercial and Medicaid payer perspectives
por: Miller, Jeffrey D, et al.
Publicado: (2015)

Tumor Necrosis Factor-Blocker Dose Escalation in Rheumatoid Arthritis Patients in a Pharmacy Benefit Management Setting
por: Blume, Steven W., et al.
Publicado: (2013)

Application of a validated algorithm to estimate the effectiveness and cost of biologics for rheumatoid arthritis in the US pharmacy benefit manager context
por: Wu, Ning, et al.
Publicado: (2015)

Assessing the Association of Formulary Copayment Changes with Real-World Treatment Patterns in Patients with Rheumatoid Arthritis on Etanercept
por: Bonafede, Machaon, et al.
Publicado: (2020)

Comorbidities as a driver of the excess costs of community-acquired pneumonia in U.S. commercially-insured working age adults
por: Polsky, Daniel, et al.
Publicado: (2012)

Short- and longer-term health-care resource utilization and costs associated with acute ischemic stroke
por: Johnson, Barbara H, et al.
Publicado: (2016)

Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis
por: Cannon, Grant W., et al.
Publicado: (2016)

Treatment patterns and economic outcomes in patients with juvenile idiopathic arthritis
por: Marshall, Alexander, et al.
Publicado: (2019)

Drug and Medical Cost Effects of a Drug Formulary Change With Therapeutic Interchange for Statin Drugs in a Multistate Managed Medicaid Organization
por: Meissner, Brian, et al.
Publicado: (2006)

Health Care Costs and Thromboembolic Events in Hydroxyurea-Treated Patients with Polycythemia Vera
por: Parasuraman, Shreekant V., et al.
Publicado: (2018)

High Body Mass Index is Associated with Shorter Retention of Tumor Necrosis Factor-Alpha Blocker Treatment in Rheumatoid Arthritis
por: Elalouf, Ofir, et al.
Publicado: (2021)

Healthcare utilization and cost of cancer-related care prior to allogeneic hematopoietic cell transplantation for hematologic malignancies in the US: a retrospective real-world analysis
por: Bonafede, Machaon, et al.
Publicado: (2021)

Retrospective analysis to describe associations between tumor necrosis factor alpha inhibitors and COPD-related hospitalizations
por: Accortt, Neil A, et al.
Publicado: (2017)

Medical costs associated with cardiovascular events among high-risk patients with hyperlipidemia
por: Bonafede, Machaon M, et al.
Publicado: (2015)

Tumor Necrosis Factor Alpha Blocker-Induced Erythrodermic Sarcoidosis in with Juvenile Rheumatoid Arthritis: A Case Report and Review of the Literature
por: Park, Su-Kyung, et al.
Publicado: (2017)

Factors Associated With Emergency Department Visits: A Multistate Analysis of Adult Fee-for-Service Medicaid Beneficiaries
por: Agarwal, Parul, et al.
Publicado: (2016)

A Cost per Responder Model for Abatacept versus Adalimumab Among Rheumatoid Arthritis Patients with Seropositivity
por: Park, Sang Hee, et al.
Publicado: (2020)

Erratum in: Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy
por: Caporali, Roberto, et al.
Publicado: (2022)

A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA
por: Wehler, Elizabeth, et al.
Publicado: (2019)

The direct and indirect costs of adult atopic dermatitis
por: Manjelievskaia, Janna, et al.
Publicado: (2021)

Medication usage, treatment intensification, and medical cost in patients with type 2 diabetes: a retrospective database study
por: Bonafede, Machaon, et al.
Publicado: (2016)

Real-World Health Care Resource Utilization and Costs Among US Patients with Knee Osteoarthritis Compared with Controls
por: Bedenbaugh, Angela V, et al.
Publicado: (2021)

Correction to: A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA
por: Wehler, Elizabeth, et al.
Publicado: (2019)

Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada
por: Weijers, Laure, et al.
Publicado: (2017)

The Medicaid Cost of Palivizumab
por: Ambrose, Christopher S., et al.
Publicado: (2015)

Predicting treatment response to IL6R blockers in rheumatoid arthritis
por: Nouri, Bako, et al.
Publicado: (2020)

Annual costs among patients with major depressive disorder and the impact of key clinical events
por: Cutler, Andrew J, et al.
Publicado: (2022)

Response to Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis for Function and Pain is Affected by Rheumatoid Factor
por: Aberumand, Babak, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_qr8blcv3hnk9go7tegkb9ara2i